MediWound (NASDAQ:MDWD) Rating Lowered to Sell at StockNews.com

MediWound (NASDAQ:MDWD) was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating in a report issued on Monday.

Other analysts have also recently issued research reports about the company. Oppenheimer cut their price objective on MediWound from $63.00 to $36.00 and set an “outperform” rating on the stock in a research note on Thursday, August 17th. HC Wainwright reaffirmed a “buy” rating and set a $23.00 target price on shares of MediWound in a report on Thursday, August 17th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $28.00.

MediWound Stock Performance

Shares of NASDAQ:MDWD traded down $0.28 during trading on Monday, hitting $8.82. The company’s stock had a trading volume of 15,409 shares, compared to its average volume of 24,770. The stock’s 50-day moving average price is $8.99 and its two-hundred day moving average price is $10.29. MediWound has a fifty-two week low of $7.10 and a fifty-two week high of $14.58. The company has a market capitalization of $81.20 million, a PE ratio of -3.63 and a beta of 1.09.

MediWound (NASDAQ:MDWD) last announced its quarterly earnings data on Tuesday, August 15th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.41) by $0.51. MediWound had a negative return on equity of 71.45% and a negative net margin of 55.53%. The firm had revenue of $4.77 million for the quarter, compared to analysts’ expectations of $4.19 million. On average, equities analysts predict that MediWound will post -1.53 earnings per share for the current fiscal year.

Hedge Funds Weigh In On MediWound

A number of institutional investors and hedge funds have recently added to or reduced their stakes in MDWD. Renaissance Technologies LLC boosted its stake in MediWound by 3.8% during the 2nd quarter. Renaissance Technologies LLC now owns 475,422 shares of the biopharmaceutical company’s stock valued at $875,000 after purchasing an additional 17,600 shares in the last quarter. Alyeska Investment Group L.P. bought a new position in MediWound during the 1st quarter valued at $1,998,000. Wells Fargo & Company MN boosted its stake in MediWound by 16.0% during the 2nd quarter. Wells Fargo & Company MN now owns 112,727 shares of the biopharmaceutical company’s stock valued at $1,202,000 after purchasing an additional 15,535 shares in the last quarter. Sphera Funds Management LTD. boosted its stake in MediWound by 47.4% during the 1st quarter. Sphera Funds Management LTD. now owns 111,127 shares of the biopharmaceutical company’s stock valued at $1,480,000 after purchasing an additional 35,714 shares in the last quarter. Finally, Sargent Investment Group LLC boosted its stake in MediWound by 2.4% during the 2nd quarter. Sargent Investment Group LLC now owns 103,190 shares of the biopharmaceutical company’s stock valued at $1,100,000 after purchasing an additional 2,389 shares in the last quarter. 22.32% of the stock is owned by institutional investors.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.